Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (9954)	5/14/1999 8:59:00 AM
From: WTDEC	Read Replies (1) \| Respond to of 17367

XOMA Concludes Patient Enrollment in NEUPREX Meningococcemia Phase III Pivotal Trial BERKELEY, Calif.--(BW HealthWire)--May 14, 1999--XOMA Ltd. (Nasdaq: XOMA - news) today announced that it has concluded patient accrual in the Phase III pivotal trial of its NEUPREX® product in patients with severe pediatric meningococcemia, a deadly bacterial infection that primarily affects children. The decision to close enrollment was made after consultation with the U.S. Food and Drug Administration (FDA). This double-blinded, placebo-controlled trial has enrolled nearly 400 patients at U.S. and U.K. hospitals, making it the largest controlled therapeutic clinical trial ever conducted in this disease